Stada and Xbrane have expanded their biosimilar development alliance by adding the Swedish firm’s certolizumab and nivolumab pre-clinical programs to the partnership.
Stada Arzneimittel and Xbrane Biopharma have expanded their strategic biosimilar development partnership to cover pre-clinical programs for certolizumab pegol and nivolumab, as well as potentially other early-stage candidates.
“Xbrane and Stada will focus on biosimilars to originator products with patent expiration 2025-2030 and have identified two programs in Xbrane’s pre-clinical biosimilar portfolio for potential future collaboration: Xcimzane (certolizumab...
Fresh from filing a proposed biosimilar to Xolair (omalizumab) in the UK, Alvotech and Advanz have shaken hands on a further deal to expand their partnership.
Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.
Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.
Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.
Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.
Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.
Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.
